Secondary Care - Continuous Glucose Monitoring

CompletedOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

March 19, 2018

Primary Completion Date

August 25, 2021

Study Completion Date

August 25, 2021

Conditions
Diabetes Mellitus, Type 2
Interventions
DEVICE

continuous glucose monitoring (CGM) iPro™2 Medtronic

A CGM device is to be set and take off by the diabetologist. Before the study start all diabetologist not familiar to the method will have a short education on CGM device. Study period is seven days and includes screening before study entry and two visits. On Day 1, after screening and signing the informed consent, the CGM device is applied. Patient is instructed to keep a 7 day diary with four daily standard SMBG along with the data on eating, physical exercise, drugs. On Day 7, CGM device is taken off and the data from iPro2 is uploaded to PC. At the end, each patient fills a short query on satisfaction while wearing CGM.

Trial Locations (1)

10 000

University Hospital Centre Zagreb, Zagreb

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Takeda

INDUSTRY

lead

Croatian Society for Endocrinology and Diabology

OTHER